BEVERLY HILLS, Calif., March 12, 2015 /PRNewswire/ -- Rich Pharmaceuticals, Inc. (OTCQB: RCHA) (“Rich Pharmaceuticals” or the “Company”), a clinical-stage biotechnology company focused on developing innovative therapies in oncology, with initial concentration in treating Acute Myelocytic Leukemia (AML) and Hodgkin’s Lymphoma, announced that Dr. Chittima Sirijerachai has committed to becoming a principal investigator (PI) for the upcoming AML clinical trial utilizing Rich’s flagship compound RP-323.
As a principal investigator, Dr. Sirijerachai will enroll patients and serve as a liaison for Rich Pharmaceuticals and supervise some of Rich’s clinical study initiatives outside the United States. Dr. Sirijerachai received her Diploma in Medical Education from the University Of Wales College Of Medicine, Cardiff, England and Diplomas from the Thai Board of Hematology and Internal Medicine at the Royal College of Physician of Thailand and is currently on the Faculty of Medicine at Khon-Kaen University.
“We are honored to have Dr. Chittima Sirijerachai agree to become a PI for Rich Pharmaceuticals,” said Ben Chang, Chief Executive Officer of the Company. “We greatly value her expertise and guidance in our planned clinical trials. In addition, we continue to aggressively push ahead with our AML clinical plans and with Therinova’s clinical research expertise in oncology, we are confident in our regulatory approval strategy,” continued Ben Chang.
About Rich Pharmaceuticals:
Rich Pharmaceuticals, Inc. (OTCQB: RCHA) is a biopharmaceutical company developing a treatment for Acute Myelocytic Leukemia (AML)/white blood cell elevation, Hodgkin’s Lymphoma and other blood related diseases. Rich Pharmaceuticals’ goal is to extend refractory patients life expectancy and increase quality of life. Rich Pharmaceuticals’ primary development stage product candidate, RP-323, is being designed to treat blood and cancer related diseases through non-evasive outpatient facilities. Find out more at www.richpharmaceuticals.com.
For more information about AML see for example:
http://www.cancer.gov/cancertopics/pdq/treatment/adultAML/Patient/page1
http://www.cancer.org/cancer/leukemia-acutemyeloidaml/
For more information about Hodgkin’s Lymphoma see for example:
http://www.cancer.gov/cancertopics/types/hodgkin
http://www.cancer.org/cancer/hodgkindisease/
Notice Regarding Forward-Looking Statements:
This news release contains “forward-looking statements” as that term is defined in Section 27(a) of the Securities Act of 1933, as amended, and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements in this press release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, references to novel technologies and methods, our business and product development plans, our financial projections or market information. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with developing new products or technologies and operating as a development stage company, our ability to raise the additional funding we will need to continue to pursue our business and product development plans, our ability to develop and commercialize products based on our technology platform, competition in the industry in which we operate and market conditions. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in the reports and other documents we file with the SEC, available at www.sec.gov.
Contact: Ben Chang, CEO, 424-230-7001 EXT 105
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/rich-pharmaceuticals-inc-names-chittima-sirijerachai-md-as-principal-investigator-for-upcoming-aml-clinical-trials-300049629.html
SOURCE Rich Pharmaceuticals, Inc.
Help employers find you! Check out all the jobs and post your resume.
